Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets
Interleukin-7 (IL-7) is a homeostatic cytokine for resting T cells with increasing serum and
tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts marked …
tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts marked …
[HTML][HTML] Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets
C Sportès, FT Hakim, SA Memon, H Zhang… - The Journal of …, 2008 - ncbi.nlm.nih.gov
Abstract Interleukin-7 (IL-7) is a homeostatic cytokine for resting T cells with increasing
serum and tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts …
serum and tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts …
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets
C Sportes, FT Hakim, SA Memon… - Journal of …, 2008 - augusta.elsevierpure.com
Abstract Interleukin-7 (IL-7) is a homeostatic cytokine for resting T cells with increasing
serum and tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts …
serum and tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts …
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets
C Sportès, FT Hakim, SA Memon… - Journal of …, 2008 - pure.johnshopkins.edu
Abstract Interleukin-7 (IL-7) is a homeostatic cytokine for resting T cells with increasing
serum and tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts …
serum and tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts …
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets
C Sportès, FT Hakim, SA Memon… - The Journal of …, 2008 - pubmed.ncbi.nlm.nih.gov
Interleukin-7 (IL-7) is a homeostatic cytokine for resting T cells with increasing serum and
tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts marked …
tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts marked …
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.
C Sportès, FT Hakim, SA Memon, H Zhang… - The Journal of …, 2008 - europepmc.org
Abstract Interleukin-7 (IL-7) is a homeostatic cytokine for resting T cells with increasing
serum and tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts …
serum and tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts …
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets
C Sportès, FT Hakim, SA Memon, H Zhang… - Journal of Experimental …, 2008 - cir.nii.ac.jp
抄録< jats: p> Interleukin-7 (IL-7) is a homeostatic cytokine for resting T cells with increasing
serum and tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts …
serum and tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts …
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.
C Sportès, FT Hakim, SA Memon, H Zhang… - The Journal of …, 2008 - europepmc.org
Abstract Interleukin-7 (IL-7) is a homeostatic cytokine for resting T cells with increasing
serum and tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts …
serum and tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts …